1-11 of 11
Stan B. Kaye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors

Free
Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew W. Stephens, Ronit Simantov, Srinivasu Poondru, Rich Gedrich, Scott M. Lippman, Stan B. Kaye, Craig P. Carden
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (4): 693–700.
https://doi.org/10.1158/1078-0432.CCR-14-0265
Published: 16 February 2015
View articletitled, Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors
Open the PDF for Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

Free
Debashis Sarker, Joo Ern Ang, Richard Baird, Rebecca Kristeleit, Krunal Shah, Victor Moreno, Paul A. Clarke, Florence I. Raynaud, Gallia Levy, Joseph A. Ware, Kathryn Mazina, Ray Lin, Jenny Wu, Jill Fredrickson, Jill M. Spoerke, Mark R. Lackner, Yibing Yan, Lori S. Friedman, Stan B. Kaye, Mika K. Derynck, Paul Workman, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (1): 77–86.
https://doi.org/10.1158/1078-0432.CCR-14-0947
Published: 05 January 2015
View articletitled, First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
Open the PDF for First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study

Free
Victor Moreno García, David Olmos, Carlos Gomez-Roca, Philippe A. Cassier, Rafael Morales-Barrera, Gianluca Del Conte, Elisa Gallerani, Andre T. Brunetto, Patrick Schöffski, Silvia Marsoni, Jan H.M. Schellens, Nicolas Penel, Emile Voest, Jeffrey Evans, Ruth Plummer, Richard H. Wilson, Jean Charles Soria, Josep Tabernero, Jaap Verweij, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (22): 5663–5671.
https://doi.org/10.1158/1078-0432.CCR-14-0719
Published: 13 November 2014
View articletitled, Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study
Open the PDF for Dose–Response Relationship in Phase I Clinical Trials: A European Drug Development Network (EDDN) Collaboration Study in another window
Includes: Supplementary data
Journal Articles

Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study

Free
Joo Ern Ang, Charlie Gourley, C. Bethan Powell, Hilda High, Ronnie Shapira-Frommer, Vincent Castonguay, Jacques De Greve, Tina Atkinson, Timothy A. Yap, Shahneen Sandhu, Susana Banerjee, Lee-May Chen, Michael L. Friedlander, Bella Kaufman, Amit M. Oza, Ursula Matulonis, Louise J. Barber, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, James Campbell, Lina Chen, Johann S. de Bono, Martin E. Gore, Christopher J. Lord, Alan Ashworth, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (19): 5485–5493.
https://doi.org/10.1158/1078-0432.CCR-13-1262
Published: 01 October 2013
View articletitled, Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study
Open the PDF for Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study in another window
Includes: Supplementary data
Journal Articles

First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies

Free
Timothy A. Yap, Hendrik-Tobias Arkenau, D. Ross Camidge, Suzanne George, Natalie J. Serkova, Stephen J. Gwyther, Jennifer L. Spratlin, Rohit Lal, James Spicer, Nandita M. Desouza, Martin O. Leach, Jon Chick, Srinivasu Poondru, Ramesh Boinpally, Richard Gedrich, Katie Brock, Andrew Stephens, S. Gail Eckhardt, Stan B. Kaye, George Demetri, Michelle Scurr
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (4): 909–919.
https://doi.org/10.1158/1078-0432.CCR-12-2258
Published: 14 February 2013
View articletitled, First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies
Open the PDF for First-in-Human Phase I Trial of Two Schedules of OSI-930, a Novel Multikinase Inhibitor, Incorporating Translational Proof-of-Mechanism Studies in another window
Includes: Supplementary data
Journal Articles

Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience

Free
Victor Moreno Garcia, Bristi Basu, L. Rhoda Molife, Stan B. Kaye
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (14): 3750–3761.
https://doi.org/10.1158/1078-0432.CCR-11-1275
Published: 15 July 2012
View articletitled, Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience
Open the PDF for Combining Antiangiogenics to Overcome Resistance: Rationale and Clinical Experience in another window
Journal Articles

Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials

Free
David Olmos, Richard D. Baird, Timothy A. Yap, Christophe Massard, Lorna Pope, Shahneen K. Sandhu, Gerhardt Attard, Juliet Dukes, Dionysis Papadatos-Pastos, Philippa Grainger, Stan B. Kaye, Johann S. de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (15): 5188–5196.
https://doi.org/10.1158/1078-0432.CCR-10-3019
Published: 31 July 2011
View articletitled, Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials
Open the PDF for Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials in another window
Includes: Supplementary data
Journal Articles

The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer

Free
Udai Banerji, D. Ross Camidge, Henk M.W. Verheul, Roshan Agarwal, Debashis Sarker, Stan B. Kaye, Ingrid M.E. Desar, Johanna N.H. Timmer-Bonte, S. Gail Eckhardt, Karl D. Lewis, Kathryn H. Brown, Mireille V. Cantarini, Clive Morris, Sarah M.A. George, Paul D. Smith, Carla M.L. van Herpen
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (5): 1613–1623.
https://doi.org/10.1158/1078-0432.CCR-09-2483
Published: 28 February 2010
View articletitled, The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer
Open the PDF for The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer in another window
Includes: Supplementary data
Journal Articles

The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin

Free
James Witham, Melanie R. Valenti, Alexis K. De-Haven-Brandon, Susanne Vidot, Suzanne A. Eccles, Stan B. Kaye, Alan Richardson
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7191–7198.
https://doi.org/10.1158/1078-0432.CCR-07-0362
Published: 03 December 2007
View articletitled, The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin
Open the PDF for The Bcl-2/Bcl-XL Family Inhibitor ABT-737 Sensitizes Ovarian Cancer Cells to Carboplatin in another window
Journal Articles

A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies

Free
Chooi P. Lee, Maja J.A. de Jonge, Anne E. O'Donnell, Kristel L. Schothorst, Janet Hanwell, Jon B. Chick, Rik A. Brooimans, Laurel M. Adams, Daniel W. Drolet, Johann S. de Bono, Stan B. Kaye, Ian R. Judson, Jaap Verweij
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (9): 2841–2848.
https://doi.org/10.1158/1078-0432.CCR-05-1932
Published: 04 May 2006
View articletitled, A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I Study of a New Nucleoside Analogue, OSI-7836, Using Two Administration Schedules in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates

Free
Paul A. Vasey, Stan B. Kaye, Rosemary Morrison, Chris Twelves, Peter Wilson, Ruth Duncan, Alison H. Thomson, Lilian S. Murray, Tom E. Hilditch, Tom Murray, Sally Burtles, D. Fraier, E. Frigerio, Jim Cassidy, on behalf of the Cancer Research Campaign Phase I/II Committee
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (1): 83–94.
Published: 01 January 1999
View articletitled, Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates
Open the PDF for Phase I Clinical and Pharmacokinetic Study of PK1 [N-(2-Hydroxypropyl)methacrylamide Copolymer Doxorubicin]: First Member of a New Class of Chemotherapeutic Agents—Drug-Polymer Conjugates in another window